The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating Reelin gene expression

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. PubMed PMID: 25651787. Epub 2015/02/06. CA Cancer J Clin. 2015 Mar;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115–132. PubMed PMID: 26808342. Epub 2016/01/26.
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer. 2018 Sep;7(3):235–260. PubMed PMID: 30319983. Pubmed Central PMCID: PMC6167671. Epub 2018/10/16.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. PubMed PMID: 31439937. Pubmed Central PMCID: PMC6813818. Epub 2019/08/24. Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589–604.
   PubMed Web of Science ®Google Scholar
• Pascual S, Herrera I, Irurzun J, et al. New advances in hepatocellular carcinoma.World J Hepatol.2016Mar28;8(9):421–438. PubMed PMID: 27028578. Pubmed Central PMCID: PMC4807304. Epub 2016/03/31.
   PubMedGoogle Scholar
• Herrmann E, Bierer S, Gerss J, et al. Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. Oncology. 2008;74(3–4):216–222. PubMed PMID: 18714170. Epub 2008/08/21.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018Mar24; 391(10126)1163–1173. PubMed PMID: 29433850. Epub 2018/02/13.
   PubMed Web of Science ®Google Scholar
• Li W, Dong X, He C, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2019May3; 38(1)183. PubMed PMID: 31053148. Pubmed Central PMCID: PMC6499991. Epub 2019/05/06.
   PubMedGoogle Scholar
• Xia S, Pan Y, Liang Y, et al. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020 Jan;51:102610. PubMed PMID: 31918403. Pubmed Central PMCID: PMC7000339. Epub 2020/01/10.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24; 359(4):378–390. PubMed PMID: 18650514. Epub 2008/07/25.
   PubMed Web of Science ®Google Scholar
• Huang A, Zheng H, Wu Z, et al. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics. 2020;10(8):3503–3517. PubMed PMID: 32206104. Pubmed Central PMCID: PMC7069073. Epub 2020/03/25.
   PubMed Web of Science ®Google Scholar
• Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol Ther. 2018 Jul;187:31–44. PubMed PMID: 29406246. Epub 2018/02/07.
   PubMed Web of Science ®Google Scholar
• Han D, Li J, Wang H, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017 Oct;66(4):1151–1164. PubMed PMID: 28520103. Epub 2017/05/19.
   PubMed Web of Science ®Google Scholar
• Wei L, Wang X, Lv L, et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer. 2019 Oct 25; 18(1):147. PubMed PMID: 31651347. Pubmed Central PMCID: PMC6814027. Epub 2019/10/28.
   PubMed Web of Science ®Google Scholar
• Li J, Qin X, Wu R, et al. Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis. J Cell Mol Med. 2020 May;24(9):5152–5161. PubMed PMID: 32222024. Pubmed Central PMCID: PMC7205830. Epub 2020/03/30.
   PubMed Web of Science ®Google Scholar
• Xu J, Ji L, Liang Y, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020 Dec 26; 5(1):298. PubMed PMID: 33361760. Pubmed Central PMCID: PMC7762756. Epub 2020/12/29.
   PubMed Web of Science ®Google Scholar
• Zhang R, Guo C, Liu T, et al. microRNA miR-495 regulates the development of Hepatocellular Carcinoma by targeting C1q/tumor necrosis factor-related protein-3 (CTRP3). Bioengineered. 2021 Dec;12(1):6902–6912. PubMed PMID: 34516334. Epub 2021/09/14.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu X, Chen Y, et al. The abnormal expression of chromosomal region maintenance 1 (CRM1)-survivin axis in ovarian cancer and its related mechanisms regulating proliferation and apoptosis of ovarian cancer cells. Bioengineered. 2021 Dec 13. doi:10.1080/21655979.2021.2012416. PubMed PMID: 34898375. Epub 2021/12/14.
   Web of Science ®Google Scholar
• Hu S, Zhang J, Fang X, et al. Identification of microRNA hsa-miR-30c-5p as an inhibitory factor in the progression of hepatocellular carcinoma and investigation of its regulatory network via comprehensive analysis. Bioengineered. 2021 Dec;12(1):7165–7177. PubMed PMID: 34503377. Epub 2021/09/11.
   PubMed Web of Science ®Google Scholar
• Zhang H, Fang Z, Guo Y, et al. Long noncoding RNA SNHG10 promotes colorectal cancer cells malignant progression by targeting miR-3690. Bioengineered. 2021 Dec;12(1):6010–6020. PubMed PMID: 34477483. Epub 2021/09/04.
   PubMed Web of Science ®Google Scholar
• Ishii K, Kohno T, Hattori M, et al. Differential binding of Anti-Reelin monoclonal antibodies reveals the characteristics of Reelin protein under various conditions.Biochem Biophys Res Commun.2019Jun30;514(3):815–820. PubMed PMID: 31079931. Epub 2019/05/14.
   PubMed Web of Science ®Google Scholar
• Pan S, Deng Y, Fu J, et al. TRIM52 promotes colorectal cancer cell proliferation through the STAT3 signaling. Cancer Cell Int. 2019;19(1):57. PubMed PMID: 30918473. Pubmed Central PMCID: PMC6419475. Epub 2019/03/29.
   PubMedGoogle Scholar
• Li L, Guo L, Yin G, et al. Upregulation of circular RNA circ_0001721 predicts unfavorable prognosis in osteosarcoma and facilitates cell progression via sponging miR-569 and miR-599. Biomed Pharmacother. 2019 Jan;109:226–232. PubMed PMID: 30396080. Epub 2018/11/06.
   PubMed Web of Science ®Google Scholar
• Qiu L, Xu H, Ji M, et al. Circular RNAs in hepatocellular carcinoma: biomarkers, functions and mechanisms. Life Sci. 2019 Aug 15; 231:116660. PubMed PMID: 31319086. Epub 2019/07/19.
   PubMed Web of Science ®Google Scholar
• Han TS, Hur K, Cho HS, et al.Epigenetic associations between lncRNA/circRNA and miRNA in hepatocellular carcinoma.Cancers (Basel).2020 Sep 14;12(9):2622. PubMed PMID: 32937886. Pubmed Central PMCID: PMC7565033. Epub 2020/09/18.
   PubMed Web of Science ®Google Scholar
• Qiu LP, Wu YH, Yu XF, et al. The emerging role of circular RNAs in hepatocellular carcinoma. J Cancer. 2018;9(9):1548–1559. PubMed PMID: 29760792. Pubmed Central PMCID: PMC5950583. Epub 2018/05/16.
   PubMed Web of Science ®Google Scholar
• Xiong D, He R, Dang Y, et al. The latest overview of circRNA in the progression, diagnosis, prognosis, treatment, and drug resistance of hepatocellular carcinoma. Front Oncol. 2020;10:608257. PubMed PMID: 33680930. Pubmed Central PMCID: PMC7928415. Epub 2021/03/09.
   PubMed Web of Science ®Google Scholar
• Ishii K, Kubo KI, Nakajima K. Reelin and neuropsychiatric disorders. Front Cell Neurosci. 2016;10:229. PubMed PMID: 27803648. Pubmed Central PMCID: PMC5067484. Epub 2016/11/03.
   PubMed Web of Science ®Google Scholar
• Okamura Y, Nomoto S, Kanda M, et al. Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann Surg Oncol. 2011 Feb;18(2):572–579. PubMed PMID: 20734148. Epub 2010/08/25.
   PubMed Web of Science ®Google Scholar
• Luo Y, Huang K, Zheng J, et al. TGF-beta1 promotes cell migration in hepatocellular carcinoma by suppressing reelin expression. Gene. 2019 Mar 10;688:19–25. PubMed PMID: 30447345. Epub 2018/11/18.
   PubMed Web of Science ®Google Scholar
• Du Y, Song W, Chen J, et al. The potassium channel KCa3.1 promotes cell proliferation by activating SKP2 and metastasis through the EMT pathway in hepatocellular carcinoma. Int J Cancer. 2019 Jul 15; 145(2):503–516. PubMed PMID: 30628729. Epub 2019/01/11.
   PubMed Web of Science ®Google Scholar
• Guan Y, Zhang Y, Hao L, et al. CircRNA_102272 promotes cisplatin-resistance in hepatocellular carcinoma by decreasing miR-326 targeting of RUNX2. Cancer Manag Res. 2020;12:12527–12534. PubMed PMID: 33324096. Pubmed Central PMCID: PMC7732977. Epub 2020/12/17.
   PubMed Web of Science ®Google Scholar